Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2023-11-16 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements, specifically multi-year global licensing agreements, and the completion of acquisition or disposition of assets. It includes references to exhibits and states that financial information will be filed later. There is no detailed financial data or comprehensive report content, but rather an announcement of significant corporate events and agreements. This fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not constitute a full financial report or other specific filing type.
2023-11-16 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 15, 2023. It announces the issuance of a press release regarding the company's financial results for the third quarter ended September 30, 2023, and references the Quarterly Report on Form 10-Q filed the same day. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release and references the 10-Q filing. The length is 3891 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the 10-Q) and a press release, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes current reports like Form 8-K that announce events or releases.
2023-11-15 English
QUARTERLY REPORT
Interim / Quarterly Report Q3 2023
2023-11-15 English
NOTIFICATION OF LATE FILING
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 filed with the SEC, which is a Notification of Late Filing for a Form 10-Q quarterly report for the period ended September 30, 2023. It explains the reason for the delay in filing the quarterly report and states that the report will be filed shortly. The document does not contain the actual financial statements or substantive financial data of the 10-Q report itself, but rather is a notification about the delay. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to the filing process and not the report itself.
2023-11-14 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce material events or agreements. The text describes the entry into a material definitive agreement involving a convertible note and a waiver letter agreement related to default conditions. It includes details about the securities purchase agreement and the letter agreement but does not contain comprehensive financial statements or detailed financial analysis. The document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing announcing a material event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5430 characters, which is sufficient for a substantive filing but the content aligns with a material event announcement rather than a full report.
2023-09-13 English
AMENDMENT NO. 1 TO FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is a current report used to disclose material events or agreements. The text describes an amendment to a cooperation agreement related to a transaction, including details about share issuance limits. It includes an exhibit attachment and a signature from the CEO. The document is relatively short (4040 characters) and focuses on announcing a material definitive agreement amendment rather than providing full financial statements or detailed financial analysis. Therefore, it is best classified as a Capital/Financing Update (CAP) because it relates to a material agreement affecting the company's capital structure (share issuance).
2023-09-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.